Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

In this 12-week phase 2 trial, a humanized anti–interleukin-17 monoclonal antibody was effective for chronic plaque psoriasis. Larger studies of longer duration are necessary to assess the safety and efficacy of long-term treatment. Psoriasis vulgaris (plaque psoriasis) is a chronic, frequently pain...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2012-03, Vol.366 (13), p.1190-1199
Hauptverfasser:	Leonardi, Craig, Matheson, Robert, Zachariae, Claus, Cameron, Gregory, Li, Linda, Edson-Heredia, Emily, Braun, Daniel, Banerjee, Subhashis
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Biological and medical sciences Clinical trials Cytokines Dermatology Dose-Response Relationship, Drug Double-Blind Method Female General aspects Humans Inflammation Injections, Subcutaneous Interleukin 17 Interleukin-17 - antagonists & inhibitors Interleukin-17 - immunology Light therapy Lymphocytes T Male Medical sciences Middle Aged Monoclonal antibodies Patients Psoriasis Psoriasis - drug therapy Psoriasis. Parapsoriasis. Lichen Severity of Illness Index Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!